The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three

Key Opinion Leaders Help to Foster Robust, Viable Pharmaceutical and Biotechnology Pipelines Imagine a world where pharmaceutical and biotechnology companies developed therapies without input from KOLs at various stages of product discovery and development. The results would be far fewer treatments available, greater risks for unwanted side effects and potentially, a larger number of unnecessary …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three Read More »